Compare NP & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NP | IRTC |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | 2025 | 2016 |
| Metric | NP | IRTC |
|---|---|---|
| Price | $28.21 | $120.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 16 |
| Target Price | $34.00 | ★ $171.33 |
| AVG Volume (30 Days) | ★ 471.5K | 420.3K |
| Earning Date | 10-20-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | ★ 0.28 | N/A |
| Revenue | N/A | ★ $747,138,000.00 |
| Revenue This Year | $26.63 | $19.40 |
| Revenue Next Year | $17.59 | $16.65 |
| P/E Ratio | $180.44 | ★ N/A |
| Revenue Growth | N/A | ★ 26.24 |
| 52 Week Low | $14.78 | $100.70 |
| 52 Week High | $35.15 | $210.01 |
| Indicator | NP | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 66.23 |
| Support Level | $26.86 | $119.48 |
| Resistance Level | $29.01 | $125.38 |
| Average True Range (ATR) | 1.03 | 3.94 |
| MACD | 0.14 | 1.82 |
| Stochastic Oscillator | 37.29 | 92.89 |
Neptune Insurance Holdings Inc is a high-growth, profitable, data-driven MGA that offers residential and commercial insurance products, including primary flood insurance, excess flood insurance and parametric earthquake insurance, distributed through a nationwide network of agencies in the United States. The company underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies and does not take any balance sheet insurance risk or have claims handling responsibility relating to the policies it sells.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.